[EN] PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSÉS DE PYRAZOLE UTILES DANS LE TRAITEMENT D'UNE INFLAMMATION
申请人:BIOLIPOX AB
公开号:WO2006032851A1
公开(公告)日:2006-03-30
There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.
[EN] 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS<br/>[FR] DERIVES PYRIMIDINYLE 2,4-BISUSBTITUES UTILES EN TANT QU'AGENTS ANTICANCEREUX
申请人:AMGEN INC
公开号:WO2003018021A1
公开(公告)日:2003-03-06
The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
该发明涵盖了化合物、类似物、前药及其药物学上可接受的盐、药物组合物、用途以及预防和治疗癌症的方法。
Substituted pyrimidinyl derivatives and methods of use
申请人:——
公开号:US20040063705A1
公开(公告)日:2004-04-01
The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
本发明涵盖化合物、类似物、前药及其药学上可接受的盐、制药组合物、用途和预防和治疗癌症的方法。
Pyrazole Compounds Useful In The Treatment Of Inflammation
申请人:Nilsson Peter
公开号:US20070225318A1
公开(公告)日:2007-09-27
There is provided compounds of formula (I), wherein R
1
, R
2
, R
a
and R
b
have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.
PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS
申请人:Burger Matthew
公开号:US20100249126A1
公开(公告)日:2010-09-30
Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.